BioElectronics Announces Western European Expansion 4 minutes ago - Market Wire
BIEL 0.0267 0.00%
As of 10:03 AM ET 7/16/09 BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced expansion into the Western European market via a strategic distribution agreement with Jumatro BV of the Netherlands. Jumatro is partnering with one of the largest pharmacy distributors in Europe to market the patented RecoveryRx(TM) brand of portable surgical recovery PEMF devices and is introducing the ActiPatch(R) Therapy brand into high-end and drug store retailers. "We are already seeing strong successes in the Benelux, having recently begun selling BioElectronics' product in the region's largest online drugstore and we have strong interest among high-end drug store retailers," commented Gerard Lindhout, General Manager of Jumatro BV. "In addition to targeting both the professional and retail markets in conjunction with major European distributors, we are also developing a web environment called Gezondheidsstad (in English: Health City) to support online sales. I have used the ActiPatch product myself with great success and believe its drug-free approach to pain relief and healing is consistent with the needs of the European market. We look forward to working with BioElectronics to take these products across Western Europe and into Germany and Spain in particular." Andrew Whelan, CEO of BioElectronics, added, "We selected a very strong partner to service Western Europe. Both Jumatro and Mr. Gerard have strong track records of success in the European markets. We look forward to supporting their European distribution expansion."
Posts: 406 | From: San Diego | Registered: Jun 2009
| IP: Logged |
posted
Up to .0285, + 6.74%. Had lots of selling early on, maybe broke free of that selling pressure? MIGHT be a good one today, but always do your own research.
Posts: 406 | From: San Diego | Registered: Jun 2009
| IP: Logged |
posted
Up to .0298, +11.61%. I could be wrong, but this is setting up to look like a break out. Just my opinion though, don't take my word for it, obviously.
Posts: 406 | From: San Diego | Registered: Jun 2009
| IP: Logged |
posted
Thanks - I have El Mucho losses to nake up for! Eddie Bauer and a few others killed me.
Good Luck to us all.
Are you in BHWF? I am - and am hoping the RM excitement will make me back all my losses by the "big news" on Monday.
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003
| IP: Logged |
posted
Sheesh, took a tumble. The Stochastic was showing heavily overbought. Needed that decrease, I think. Its climbing back it looks like. Was oversold a second ago.
Posts: 406 | From: San Diego | Registered: Jun 2009
| IP: Logged |
Chart says the price is under its lower bollinger band, so its lower than it should be. And both the stochastic oscillator and Williams %R show that its heavily oversold. Chart says that the selling pressure should end any second now, and the price should correct itself. Always do your own research.
.0275
Posts: 406 | From: San Diego | Registered: Jun 2009
| IP: Logged |
posted
dang - looks like I'm getting pinched by a stinky pinky again! I need to go to a meeting - won't be back before 3. If I'm down IO'll probably get out.
THAT's good for you 'cuz THEN it will ROCKET !!
"Miss it by THIS Much" !!
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003
| IP: Logged |
posted
FREDERICK, MD--(Marketwire - July 29, 2009) - BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, held a conference call yesterday morning, a replay of which is available by dialing (888) 203-1112 and entering passcode 4461002.
"We were once again able to exceed our wildest expectations relative to investor attendance with nearly 1,200 dialing in to hear the presentations. Investors continue to aggressively seek information about our unique patented, drug-free alternatives to pain management and healing," commented Andrew Whelan, CEO of BioElectronics, Corp. "Our goal is to revolutionize pain management and healing. The consumer of today is conditioned to reach for a pill when they have an ache or pain. We believe we can change this consumer behavior and believe this represents a market opportunity potentially worth hundreds of millions of dollars to our company and its investors."
A summary of the conference call is provided below:
Clinical Results -- David G. Genecov, M.D. FACS FAAP, provided preliminary data on a heel and foot pain study showing strong efficacy and 100% safety using the ActiPatch device. The study also showed study participants were able to significantly reduce their use of acetaminophen, the active ingredient in Tylenol®, and non-steroidal anti-inflammatory drugs (NSAIDs). Considering the recent FDA panel recommendation relating to acetaminophen usage, these results are highly significant.
Clinical Studies and FDA Filings -- Clinical studies in the areas of breast augmentation, Cesarean section, Uveitis, and several areas of surgical recovery are quickly coming to a close with data expected over the coming months. With the data provided by the Genecov study, the management team plans to accelerate its FDA 510(k) pre-marketing clearance filing for general musculoskeletal complaints designed to lead to over-the-counter approval. In addition, the Company will soon submit an additional application of 510(k) pre-marketing clearance for general surgical recovery.
International Distribution Expansion -- International distribution relationships continue to advance at a rapid rate. The Company announced it will soon be entering the German and Spanish markets, which will augment other international markets, particularly the Italian, Korean and Canadian markets, which are already showing revenue acceleration. Several Asian distribution partnership agreements are currently being negotiated.
Financials -- Management indicated that the financial position of the Company has improved dramatically over the past few months. Further payments have been made on convertible debentures with balances dropping from more than $910,000 one year ago to less than $50,000 today. Elimination of all convertible debenture balances is likely over the coming weeks. BioElectronics is maintaining very strong gross margins and tight expense controls, resulting in the Company operating at near breakeven levels. The working capital position at the Company has also significantly improved. The recent U.S. Government Export-Import Bank guarantee is expected to further improve the working capital position.
Company Priorities -- The priorities for BioElectronics remain the completion of clinical trials, FDA submissions, expansion of international distribution, and the further development of our patented, drug-free brands: Allay, ActiPatch and RecoveryRx.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx™ Devices, HealFast™ Therapy (www.healfasttherapy.com) and the Allay™ family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Tylenol® is a registered trademark of McNeil pharmaceutical, Inc.
Looks like it could go up for a couple days now but we will see.
-------------------- Night shift stock player. Posts: 24 | From: Clovis, NM | Registered: Jul 2009
| IP: Logged |
A link to the 54 page market analyst report. Very interesting, informative, and exciting. I see this stock really going nuts in the 3-6 month period.
Posts: 44 | From: Florida | Registered: May 2009
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
